Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces preliminary outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Change in number of shares and votes in Alligator Bioscience
During the month of January, the number of shares and votes in Alligator Bioscience AB has changed as a result of the exercise of warrants s ...
The subscription period in Alligator Bioscience’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports full year financial results for 2024 and for Q4 2024 and provides a business update
Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...
Alligator Bioscience announces final terms of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 13 January 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...
Change in number of shares and votes in Alligator Bioscience
During the month of December, the number of shares and votes in Alligator Bioscience AB has changed due to conversion of a total of 170,681 ...